217 related articles for article (PubMed ID: 10716329)
1. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
8. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
9. [Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
Mutschler J; Steinbach G; Bunjes D; Reske SN; Buchmann I
Nuklearmedizin; 2009; 48(1):30-6. PubMed ID: 19212609
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Zenz T; Schlenk RF; Glatting G; Neumaier B; Blumstein N; Buchmann I; von Harsdorf S; Ringhoffer M; Wiesneth M; Keller F; Kotzerke J; Röttinger E; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
J Nucl Med; 2006 Feb; 47(2):278-86. PubMed ID: 16455634
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
13. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
14. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
15. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
16. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
18. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
19. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
